-
Je něco špatně v tomto záznamu ?
Result of the first 12 months of treatment of macular edema complicating brvo in patients treated with ranibizumab
Lalinská L., Krásný J., Studený P., Veith M.
Jazyk angličtina Země Česko
- Klíčová slova
- centrální retinální tloušťka, zisk písmen,
- MeSH
- dospělí MeSH
- humanizované monoklonální protilátky aplikace a dávkování farmakologie terapeutické užití MeSH
- injekce intravitreální metody MeSH
- klinická studie jako téma MeSH
- laserová koagulace metody MeSH
- lidé středního věku MeSH
- lidé MeSH
- makulární edém * etiologie farmakoterapie MeSH
- okluze retinální žíly * farmakoterapie komplikace MeSH
- ranibizumab * aplikace a dávkování farmakologie terapeutické užití MeSH
- retina MeSH
- senioři MeSH
- statistika jako téma MeSH
- vaskulární endoteliální růstové faktory antagonisté a inhibitory terapeutické užití MeSH
- výsledek terapie MeSH
- zraková ostrost účinky léků MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
The aim of the study: Retrospective evaluation of the first 12 months treatment of macular edema in BRVO with ranibizumab based on anatomical and functional parameters. Methods: 54 eyes with macular edema complicating BRVO were included in the study, with an average initial best corrected visual acuity 4/16 ETDRS charts, an average central retinal thickness 512.3 μm, and in average 4 months till the beginning of treatment with ranibizumab. After 3 initial injections of 0.5 mg ranibizumab treatment was performed in pro re nata regimen, with adjuvant laser (grid laser photocoagulation) as an additional treatment option. The number of injections administered, the number of eyes where grid laser photocoagulation was provided, functional parameters as a letter gain and BCVA (eyes with final BCVA ≥ 4/8 ETDRS, final BCVA in according to initial BCVA) and anatomical parameters as a mean CRT and CRT ≤ 250 μm, respectively ≤ 300 μm were evaluated. Results: In the whole group, an average of 4.8 injections of ranibizumab were administered in the first 12 months. Grid laser photocoagulation was performed in 42 eyes: in 8 eyes prior to the beginning of treatment with ranibizumab, 7 eyes before and during the treatment, 29 eyes only during the treatment. The main gain of letters after 12 months of treatment was +16.5 letters, with 63¨% (n = 34) eyes earning ≥ 15 letters. In the whole group 72 % (n = 39) eyes achieved the resulting BCVA ≥ 4/8 ETDRS after 12 months of treatment. The eyes with initial BCVA ≥ 4/10 ETDRS resulted in BCVA ≥ 4/8 ETDRS in 96 % (n = 23 eyes) and 11 eyes even achieved BCVA ≥ 4/4. The mean CRT after 12 months of treatment was 290.3 μm, 33.3 % of eyes had final CRT ≤ 250 μm, and 64.8 % had final CRT ≤ 300 μm. Conclusion: When applying a relatively low number of injections in the first year of treatment with ranibizumab, the final best corrected visual acuity was very good at the end of the observation period, and its dependence on the initial best corrected visual acuity was confirmed. Satisfactory results of central retinal thickness were found as well.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19000075
- 003
- CZ-PrNML
- 005
- 20210602022945.0
- 007
- cr|cn|
- 008
- 190104s2018 xr cd fs 000 0|eng||
- 009
- AR
- 024 0_
- $a 10.31348/2018/1/3-2-2018 $2 doi
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Lalinská, Lucia $7 xx0228453 $u Department of Ophthalmology, Královské Vinohrady University Hospital and 3rd Faculty of Medicine, Charles University Prague
- 245 10
- $a Result of the first 12 months of treatment of macular edema complicating brvo in patients treated with ranibizumab / $c Lalinská L., Krásný J., Studený P., Veith M.
- 520 3_
- $a The aim of the study: Retrospective evaluation of the first 12 months treatment of macular edema in BRVO with ranibizumab based on anatomical and functional parameters. Methods: 54 eyes with macular edema complicating BRVO were included in the study, with an average initial best corrected visual acuity 4/16 ETDRS charts, an average central retinal thickness 512.3 μm, and in average 4 months till the beginning of treatment with ranibizumab. After 3 initial injections of 0.5 mg ranibizumab treatment was performed in pro re nata regimen, with adjuvant laser (grid laser photocoagulation) as an additional treatment option. The number of injections administered, the number of eyes where grid laser photocoagulation was provided, functional parameters as a letter gain and BCVA (eyes with final BCVA ≥ 4/8 ETDRS, final BCVA in according to initial BCVA) and anatomical parameters as a mean CRT and CRT ≤ 250 μm, respectively ≤ 300 μm were evaluated. Results: In the whole group, an average of 4.8 injections of ranibizumab were administered in the first 12 months. Grid laser photocoagulation was performed in 42 eyes: in 8 eyes prior to the beginning of treatment with ranibizumab, 7 eyes before and during the treatment, 29 eyes only during the treatment. The main gain of letters after 12 months of treatment was +16.5 letters, with 63¨% (n = 34) eyes earning ≥ 15 letters. In the whole group 72 % (n = 39) eyes achieved the resulting BCVA ≥ 4/8 ETDRS after 12 months of treatment. The eyes with initial BCVA ≥ 4/10 ETDRS resulted in BCVA ≥ 4/8 ETDRS in 96 % (n = 23 eyes) and 11 eyes even achieved BCVA ≥ 4/4. The mean CRT after 12 months of treatment was 290.3 μm, 33.3 % of eyes had final CRT ≤ 250 μm, and 64.8 % had final CRT ≤ 300 μm. Conclusion: When applying a relatively low number of injections in the first year of treatment with ranibizumab, the final best corrected visual acuity was very good at the end of the observation period, and its dependence on the initial best corrected visual acuity was confirmed. Satisfactory results of central retinal thickness were found as well.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a okluze retinální žíly $x farmakoterapie $x komplikace $7 D012170
- 650 12
- $a makulární edém $x etiologie $x farmakoterapie $7 D008269
- 650 12
- $a ranibizumab $x aplikace a dávkování $x farmakologie $x terapeutické užití $7 D000069579
- 650 _2
- $a klinická studie jako téma $7 D000068456
- 650 _2
- $a injekce intravitreální $x metody $7 D058449
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a humanizované monoklonální protilátky $x aplikace a dávkování $x farmakologie $x terapeutické užití $7 D061067
- 650 _2
- $a vaskulární endoteliální růstové faktory $x antagonisté a inhibitory $x terapeutické užití $7 D042442
- 650 _2
- $a laserová koagulace $x metody $7 D017075
- 650 _2
- $a retina $7 D012160
- 650 _2
- $a zraková ostrost $x účinky léků $7 D014792
- 650 _2
- $a statistika jako téma $7 D013223
- 653 00
- $a centrální retinální tloušťka
- 653 00
- $a zisk písmen
- 700 1_
- $a Krásný, Jan, $d 1952- $7 mzk2008430515 $u Department of Ophthalmology, Královské Vinohrady University Hospital and 3rd Faculty of Medicine, Charles University Prague
- 700 1_
- $a Studený, Pavel, $u Department of Ophthalmology, Královské Vinohrady University Hospital and 3rd Faculty of Medicine, Charles University Prague $d 1968- $7 xx0098109
- 700 1_
- $a Veith, Miroslav $u Department of Ophthalmology, Královské Vinohrady University Hospital and 3rd Faculty of Medicine, Charles University Prague $7 xx0228135
- 773 0_
- $t Czech and Slovak Ophthalmology $g Roč. 5, č. 2 (2018), s. 62-67 $w MED00194413
- 856 41
- $u http://www.cs-ophthalmology.cz/en/journal/2018/2/3 $y plný text volně přístupný
- 910 __
- $a ABA008 $b online $y p $z 0
- 990 __
- $a 20190104132740 $b ABA008
- 991 __
- $a 20210602022944 $b ABA008
- 999 __
- $a ok $b bmc $g 1363068 $s 1038187
- BAS __
- $a 3 $a 4
- BMC __
- $a 2018 $b 5 $c 2 $d 62-67 $m Czech and Slovak Ophthalmology $x MED00194413
- LZP __
- $c NLK189 $d 20210531 $a NLK 2019-01/pk